127 related articles for article (PubMed ID: 2532554)
21. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
[TBL] [Abstract][Full Text] [Related]
22. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2.
Mitchell MS
Semin Oncol; 1992 Apr; 19(2 Suppl 4):80-7. PubMed ID: 1553579
[TBL] [Abstract][Full Text] [Related]
24. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.
Lindemann A; Höffken K; Schmidt RE; Diehl V; Kloke O; Gamm H; Hayungs J; Oster W; Böhm M; Kolitz JE
Cancer Immunol Immunother; 1989; 28(4):275-81. PubMed ID: 2784715
[TBL] [Abstract][Full Text] [Related]
25. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
[TBL] [Abstract][Full Text] [Related]
26. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
28. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.
Wersäll P; Mellstedt H
Med Oncol; 1995 Jun; 12(2):69-77. PubMed ID: 8535664
[TBL] [Abstract][Full Text] [Related]
29. A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies.
Lindemann A; Hoeffken K; Schmidt RE; Diehl V; Kloke O; Gamm H; Hayungs J; Oster W; Boehm M; Franks CR
Cancer Treat Rev; 1989 Jun; 16 Suppl A():53-7. PubMed ID: 2670215
[TBL] [Abstract][Full Text] [Related]
30. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
[TBL] [Abstract][Full Text] [Related]
31. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
32. High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
Quan WD; Walker PR; Picton M; Quan FM; King LA; Tyre C; Liles DK
Cancer Biother Radiopharm; 2008 Oct; 23(5):641-6. PubMed ID: 18999936
[TBL] [Abstract][Full Text] [Related]
33. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
Mitchell MS; Kan-Mitchell J; Kempf RA; Harel W; Shau HY; Lind S
Cancer Res; 1988 Oct; 48(20):5883-93. PubMed ID: 3262416
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.
Dutcher JP; Creekmore S; Weiss GR; Margolin K; Markowitz AB; Roper M; Parkinson D; Ciobanu N; Fisher RI; Boldt DH
J Clin Oncol; 1989 Apr; 7(4):477-85. PubMed ID: 2647913
[TBL] [Abstract][Full Text] [Related]
35. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.
Flaherty LE; Redman BG; Chabot GG; Martino S; Gualdoni SM; Heilbrun LK; Valdivieso M; Bradley EC
Cancer; 1990 Jun; 65(11):2471-7. PubMed ID: 2337862
[TBL] [Abstract][Full Text] [Related]
36. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
[TBL] [Abstract][Full Text] [Related]
37. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
38. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.
Paciucci PA; Holland JF; Glidewell O; Odchimar R
J Clin Oncol; 1989 Jul; 7(7):869-78. PubMed ID: 2661733
[TBL] [Abstract][Full Text] [Related]
39. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study.
Reddy SP; Harwood RM; Moore DF; Grimm EA; Murray JL; Vadhan-Raj S
J Immunother; 1997 Jan; 20(1):79-87. PubMed ID: 9101417
[TBL] [Abstract][Full Text] [Related]
40. Sustained indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced malignant melanoma: a phase II study.
Mertens WC; Bramwell VH; Banerjee D; Gwadry-Sridhar F; Lala PK
Clin Oncol (R Coll Radiol); 1993; 5(2):107-13. PubMed ID: 8481359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
